The effect of dopamine receptor blocking on esophageal sensitivity in healthy volunteers

The effect of chlorpromazine (Largactil), a dopamine type 2-(D2-) receptor antagonist, on esophageal sensitivity in healthy volunteers: a randomized, double-blind, placebo-controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-003131-38-BE

Enrollment

Registered

2017-05-08

Start date

2017-06-23

Completion date

Unknown

Last updated

2021-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Increased esophageal sensitivity in refractory gastro-esophageal reflux disease

Interventions

Trade Name: Largactil 25mg/5ml Product Name: Largactil 25mg/5ml Pharmaceutical Form: Concentrate for solution for injection Pharmaceutical form of the placebo: Concentrate for solution for injection R

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age > 18 and =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. history of any upper GI symptoms or GI surgery 2. Psychological disorders 3. Any drug history 4. Use of medication altering esophageal or GI motility 5.Pregnant or nursing women

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the effect of chlorpromazine (Largactil) on esophageal sensitivity in healthy subjects;Secondary Objective: not applicable;Primary end point(s): To assess the effect of chlorpromazine (Largactil) on esophageal sensitivity in healthy subjects by using a multimodal stimulation protocol;Timepoint(s) of evaluation of this end point: after administration of chlorpromazine (Largatil)	—

Measure

Time frame

Main Objective: To investigate the effect of chlorpromazine (Largactil) on esophageal sensitivity in healthy subjects;Secondary Objective: not applicable;Primary end point(s): To assess the effect of chlorpromazine (Largactil) on esophageal sensitivity in healthy subjects by using a multimodal stimulation protocol;Timepoint(s) of evaluation of this end point: after administration of chlorpromazine (Largatil)

—

Secondary

Measure	Time frame
Secondary end point(s): not applicable;Timepoint(s) of evaluation of this end point: not applicable	—

Countries

Belgium

Contacts

Public ContactTARGID

TARGID, KU Leuven

charlotte.broers@kuleuven.be3216330671

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026